The recall concerns any parallel imported stock of Lots A200127, A216454 and A229505 (and lot variants).
Class 1 is the most serious drug alert and action should be taken immediately as there is a serious risk to a patient's health.
The counterfeit material was supplied in French livery via parallel distributors into the UK supply chain. Both genuine Lilly manufactured product and counterfeit product may be present in the UK supply chain.
Recipients of this counterfeit stock are asked to attempt to recover tablets from patients and quarantine all remaining stock. All recovered stock should be returned to Eli Lilly, not the original stock supplier.
The full MHRA statement can be found on their website.